Host-vs-Graft Disease

Lethal Syndrome Prevented by Early Injections of Anti-Interleukin-4 Monoclonal Antibody

Published in Blood Weekly, June 29th, 2000

Lethal host-vs-graft (HVG) syndrome can be prevented with early injections of anti-interleukin-4 (anti-IL-4) monoclonal antibody (MAb), researchers in the United States reported.

"Lethal HVG syndrome is the rapidly progressive disease that follows the perinatal inoculation of semiallogeneic donor spleen cells into susceptible strains of mice," said R.C. Hard and colleagues from the Medical College of Virginia. "RFM/(T6xRFM)F1 chimeras are dead in 30 days with lymphosplenomegaly, nephropathic immune complexes, and excessive serum levels of IgG1 [immunoglobulin G1] and IgE. The aim of this study was to modulate the effects of the allogeneic HVG reaction on B cells...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2000-06-29)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry